Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 452

1.

The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.

Martin K, Wiesner G, Breuer T, Lange R, Tassani P.

Anesth Analg. 2008 Dec;107(6):1783-90. doi: 10.1213/ane.0b013e318184bc20.

PMID:
19020118
2.

The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.

Breuer T, Martin K, Wilhelm M, Wiesner G, Schreiber C, Hess J, Lange R, Tassani P.

Eur J Cardiothorac Surg. 2009 Jan;35(1):167-71; author reply 171. doi: 10.1016/j.ejcts.2008.09.038. Epub 2008 Nov 21.

PMID:
19027313
3.

Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.

Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.

Anesth Analg. 2008 Nov;107(5):1469-78. doi: 10.1213/ane.0b013e318182252b.

PMID:
18931201
4.

Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.

Maslow AD, Chaudrey A, Bert A, Schwartz C, Singh A.

J Cardiothorac Vasc Anesth. 2008 Feb;22(1):6-15. doi: 10.1053/j.jvca.2007.07.017. Epub 2007 Nov 7.

PMID:
18249324
5.

Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.

Later AF, Maas JJ, Engbers FH, Versteegh MI, Bruggemans EF, Dion RA, Klautz RJ.

Eur J Cardiothorac Surg. 2009 Aug;36(2):322-9. doi: 10.1016/j.ejcts.2008.11.038. Epub 2009 Feb 27.

PMID:
19250838
6.

Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.

Lindvall G, Sartipy U, Ivert T, van der Linden J.

Ann Thorac Surg. 2008 Jul;86(1):13-9. doi: 10.1016/j.athoracsur.2008.03.033.

PMID:
18573391
7.

The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.

Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS.

Anesth Analg. 2010 Jan 1;110(1):21-9. doi: 10.1213/ANE.0b013e3181c0ea6d. Epub 2009 Nov 12.

PMID:
19910626
8.

Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.

Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, Tassani P, Wiesner G.

J Cardiothorac Vasc Anesth. 2011 Feb;25(1):20-5. doi: 10.1053/j.jvca.2010.10.007.

PMID:
21272777
9.

Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).

Vanek T, Jares M, Fajt R, Straka Z, Jirasek K, Kolesar M, Brucek P, Maly M.

Eur J Cardiothorac Surg. 2005 Oct;28(4):563-8.

PMID:
16125959
10.

The risk associated with aprotinin in cardiac surgery.

Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation.

N Engl J Med. 2006 Jan 26;354(4):353-65.

11.

A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.

Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM.

Transfusion. 2006 Mar;46(3):327-38.

PMID:
16533273
12.

Coronary artery bypass grafting after aprotinin: are we doing better?

Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, Bolotin G.

J Thorac Cardiovasc Surg. 2013 Jan;145(1):243-8. doi: 10.1016/j.jtcvs.2012.09.032. Epub 2012 Oct 13.

13.

Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.

Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T.

Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):98-101. doi: 10.1510/icvts.2008.198325. Epub 2009 Apr 20. Review.

PMID:
19380335
14.

[Comparison of effects of aprotinin and tranexamic acid on blood loss in heart surgery].

Corbeau JJ, Monrigal JP, Jacob JP, Cottineau C, Moreau X, Bukowski JG, Subayi JB, Delhumeau A.

Ann Fr Anesth Reanim. 1995;14(2):154-61. French.

PMID:
7486272
15.

Renal dysfunction in cardiac surgery: identifying potential risk factors.

Barnum JL, Sistino JJ.

Perfusion. 2009 Mar;24(2):139-42. doi: 10.1177/0267659109106827.

PMID:
19654159
16.

A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.

Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R; BART Investigators.

N Engl J Med. 2008 May 29;358(22):2319-31. doi: 10.1056/NEJMoa0802395. Epub 2008 May 14. Erratum in: N Engl J Med. 2010 Sep 23;363(13):1290.

17.

Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.

Jakobsen CJ, Søndergaard F, Hjortdal VE, Johnsen SP.

Eur J Cardiothorac Surg. 2009 Nov;36(5):863-8. doi: 10.1016/j.ejcts.2009.05.040. Epub 2009 Sep 25.

PMID:
19782573
18.

Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.

Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C.

Crit Care. 2010;14(4):R148. doi: 10.1186/cc9216. Epub 2010 Aug 3.

19.

The effect of aprotinin on outcome after coronary-artery bypass grafting.

Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF.

N Engl J Med. 2008 Feb 21;358(8):784-93. doi: 10.1056/NEJMoa0707768.

20.

Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?

Bulutcu FS, Ozbek U, Polat B, Yalçin Y, Karaci AR, Bayindir O.

Paediatr Anaesth. 2005 Jan;15(1):41-6.

PMID:
15649162

Supplemental Content

Support Center